Skip to main content

Table 4 Comparison between patients with and without IgG4-related periaortitis/periarteritis with exacerbation of luminal dilatation after therapy

From: Clinical features of IgG4-related periaortitis/periarteritis based on the analysis of 179 patients with IgG4-related disease: a case–control study

  Univariate analysis Multivariate analysis
Parameter Exacerbation (+) Exacerbation (–) p value OR (95% CI) p value
Total 9 34    
Median onset age of IgG4-RD (years) 67 69 0.26 0.83 (0.66–1.06) 0.13
Sex (male/female) 7/2 30/4 0.42 0.75 (0.0053–108) 0.91
Luminal dilatation before treatment (+/–) 6/3 2/32 < 0.0001 93.0 (3.7–2300) 0.0057
Allergy (+/–) 2/7 11/23 0.56   
Smoking (+/–) 7/2 21/13 0.37 6.4 (0.061–660) 0.43
Hypertension (+/–) 5/4 15/19 0.54 6.3 (0.44–90) 0.18
Median IgG (mg/dl) 2451 2903 0.86 1.0004 (1.00–1.001) 0.48
Median IgG4 (mg/dl) 566 540 0.83   
Median IgE (IU/ml) 288 178 0.34   
Median WBC (/μl) 5060 6200 0.12 1.00 (0.999–1.0002) 0.15
Median RF (U/ml) 1 6 0.11 1.02 (0.99–1.04) 0.23
Median CIC (μg/ml) 10 5 0.55   
Median sIL-2R (U/ml) 1072 1149 1.00   
  1. Among the 65 IgG4-related periaortitis/periarteritis patients, 43 (66.2%) received corticosteroids. All patients showed improvement of wall thickening after therapy, although nine patients also exhibited worsening of luminal dilatation. Univariate analysis comparisons of the nine patients with luminal dilatation after corticosteroid therapy and the 34 patients without revealed prior luminal dilatation before treatment to be associated with this symptom, which was supported by multiple logistic analysis
  2. OR odds ratio, CI confidence interval, CIC circulating immune complex, CRP C-reactive protein, IgE immunoglobulin E, IgG immunoglobulin G, IgG4-RD immunoglobulin G4-related disease, RF rheumatoid factor, sIL-2R soluble interleukin-2 receptor, WBC white blood cells